- Patients
- Clinical Research
- Find a clinical trial
- LAVA-1266
Other
LAVA-1266
A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2 T cell engager, in patients with relapsed/refractory acute myeloid leukemia and intermediate risk, high risk, or extremely high risk myelodysplastic syndrome.
Trial overview
Haematology
Leukaemia
Malignant Haematology
I / II a
Registration number: ACTRN12624001214527
St Andrew's Precinct (Oncology)
Level 1, 337 South Terrace, Adelaide, SA, 5000, Australia
Haematologist
A/Prof Ian Lewis
MBBS PhD FRACP FRCPA
Elizabeth Vale (Playford Health Hub) +2

Clinical trials enquiries
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.